An important factor implicated in tumor cell predisposition for invasion and metastasis is the malignancy-related upregulation of urokinase plasminogen activator receptor (uPAR). uPAR signals by activating different tyrosine kinases in different cells. We examined the effects of inhibiting uPAR signaling by inhibition of uPAR expression with antisense oligonucleotides (aODNs) in PC3 human prostate cancer cells and evaluated aODN effect in a mouse model of prostate cancer bone metastasis. Following uPAR aODN treatment, PC3 cells exhibited a strong decrease in uPAR expression, evaluated by flow cytometry and by polymerase chain reaction, and of FAK/JNK/Jun phosphorylation. The synthesis of cyclins A, B, D1 and D3 was inhibited, as shown by Western blotting, flow cytometry and polymerase chain reaction, and PC3 cells accumulated in the G2 phase of the cell cycle. PC3 cells' adhesion was unaffected, while proliferation and invasion of Matrigel were impaired. A total of 60 mice were subjected to intracardiac injection of PC3 cells and were randomly assigned to three groups: aODN (treated with 0.5 mg intraperitoneum/mouse/day), dODN (treated with the same amounts of a degenerated ODN) and control (injected with a saline solution). At 28 days after heart injection, mice were subjected to a digital scan of total body radiography, which revealed 80% reduction in mice affected by bone metastasis. The use of uPAR aODNs produced a substantial prophylactic effect against prostate cancer bone metastasis, which has to be ascribed to downregulation of uPAR expression. Gene Therapy (2005) 12, 702-714.
Introduction
Prostate cancer (PCa) is a typical disease of the elderly, representing one of the most frequently occurring tumors in men over 60 years of age in most industrialized countries. The progression of PCa towards a malignant incurable phenotype develops frequently through the loss of the androgen-dependence and the formation of distant metastases. PCa, like breast and lung cancers, has a marked propensity to metastasize to bone that cannot be explained only by considering hemodynamic factors. Recent findings have suggested that the dissemination of cells is an early event in PCa but that it is not sufficient for development of metastases. 1 This evidence supports the idea that although the development of metastases requires several selective steps, the restrictive phases in PCa progression are represented by extravasation and secondary tumor growth. The study of the molecular mechanisms underlying the final steps in PCa metastasis formation is fundamental in order to develop new and effective antimetastatic therapies. An important factor implicated in the tumor cell predisposition for invasion and metastasis is the aberrant regulation of urokinase plasminogen activator (uPA) activity and of its receptor (uPAR, CD87). [2] [3] [4] The uPA/uPAR system supports tumor invasion and metastasis by the enzyme activity of uPARbound uPA, and by interactions of uPAR with vitronectin (VN), integrins and PAI-1, a sort of 'grip-and-go' molecular machinery, which leads to cell movement. [2] [3] [4] There is evidence that uPA/uPAR interaction also stimulates cell proliferation, [2] [3] [4] and that high expression of uPAR alone regulates the growth of some malignant cell lines in vitro and in vivo, by interacting with and activating integrins, which trigger a signaling cascade that culminates in persistent ERK activation. 5 Such an activation is additionally enhanced by uPA binding to uPAR and cell binding to fibronectin (FN). 5, 6 As a consequence, the constitutive ERK activation generated by uPAR overexpression in cancer cells maintains uPAR mRNA and protein production at high levels, sustaining the signaling cascade for cell cycle progression. 7 Following uPAR downregulation, ERK activity is reduced, p38 becomes activated, and the balance is shifted in favor of p38, 7 which induces growth arrest in malignant cells. These results have indicated that by downregulation of uPAR it is possible to disrupt the mutual interactions between uPAR, uPA and the other proteins that constitute the ERK activating complex, to force the cells to enter a state of prolonged growth arrest. In order to block uPAR-dependent invasion and proliferation in PCa cells (PC3), we have impaired uPAR expression in vitro and in vivo by uPAR antisense oligodeoxyribonucleotides (aODNs), previously used in other studies of our laboratory. 8, 9 In this study, we investigated the effectiveness of uPAR aODN treatment in inhibiting proliferation and invasion of PC3 cells in vitro, and in reducing in vivo bone metastasis in nude mice after intracardiac injection. In vitro, we have observed that aODN impairment of uPAR expression blocked PC3 cells' proliferation and invasion of reconstituted basement membranes, while adhesive properties resulted unaffected. uPAR aODN treatment strongly reduced activation of the FAK/JNK/ Jun pathway, leading to inhibition of cyclins D, A and B expression. In vivo, intraperitoneum uPAR aODN treatment of nude mice subjected to intracardiac injection of PC3 cells resulted in the 80% reduction of radiographic evident bone metastases.
Results

Activity of uPAR antisense on uPAR expression, invasion and proliferation of PC3 cells
Promotion of cell invasion, constitutive and growth factor-stimulated proliferation of normal cells, as well as the autocrine/paracrine-sustained growth of transformed cells are considered the primary functions of cellassociated uPAR.
2-4 Therefore, we expected to observe profound effects on PC3 cells' invasiveness and growth upon the uPAR antisense. For invasion, untreated PC3 cells and PC3 cells pretreated for 96 h with ODNs (as detailed in Materials and methods) were placed in the upper well of the Boyden chamber in the absence (control conditions) or in the presence of ODNs. In all the experiments described in the present and in the following paragraphs, the term 'control cells' refers to PC3 cells cultivated in the presence of DOTAP, since preliminary results have shown that cationic phospholipids do not alter either proliferation or invasion of PC3 cells. Spontaneous invasion of Matrigel was evaluated after 6 h. Figure 1 (panel a) shows the variation of Matrigel-invading cells after ODN treatment. In order to reach and to spread on the bottom side of the filter, cells must invade the Matrigel layer, cross the filter pores and adhere to the lower aspect of the filter itself. Therefore, the number of cells counted in such a location reflects cell invasion. aODN treatment specifically and significantly impaired PC3 cells' invasion, while dODN produced a nonstatistically significant difference with respect to control. We measured the kinetics of PC3 cell proliferation in the absence and in the presence of uPAR aODN and dODN in the culture medium, as described above. Figure 1 (panel b) shows the cell number reached in the growing plates by PC3 cells under control conditions (10% FCS) and over a 4 days daily treatment with ODNs (10% FCS+dODN or aODN). It is evident that PC3 cells respond to uPAR aODN with a strong decrease of proliferation. No floating cells were present at each time point following DOTAP/ODNs treatment. To validate the activity of an aODN, it is necessary to show specific inhibition of the expression of the protein encoded by the target mRNA, as well as the decrease of the relevant mRNA. Figure 1c shows the surface expression of uPAR, evaluated by flow cytometry. As shown in the picture, despite the fact that all the cells in the different culture conditions expressed CD87, the mean fluorescence intensity (MFI) was markedly lower in cells treated with aODN in respect of control and dODN-treated cultures. ELISA determination of uPAR has given similar results after 96 h ODNs treatment: control, 13.3871.21 ng/mg protein; aODN, 5.0270.75 ng/mg protein; dODN, 11.6572.25 ng/mg protein.
A segment of mRNA of the uPAR gene, including the aODN-targeted sequence, was reversely transcribed and amplified. PCR values falling within the linearity range were normalized to those of the GAPDH gene, used as an internal standard. The treatment of PC3 cells with aODN resulted in a decrease of specific uPAR mRNA ( Figure 1d ).
Studies of adhesion/spreading and proliferation on different substrates
Since uPAR regulates cell/ECM interactions as an adhesion receptor for vitronectin and through its capacity to modulate integrin function, [2] [3] [4] we performed adhesion and proliferation assays on specific substrates to test whether the observed effects on migration and proliferation could be accounted for by uPAR-dependent alterations in cell/ECM interactions. Figure 2a shows the results of cell adhesion on different substrates. By 15 min after plating, basically all the seeded cells were found adherent to each substrate, but only in the presence of vitronectin about 35% of PC3 cells achieved spreading. A total of 100% of adherent cells reached spreading within 90 min of plating regardless of the treatment and of the substrate. Vitronectin was a preferential substrate for spreading, which, however, followed slower kinetics with aODN-treated PC3 cells. Vitronectin was a preferential substrate also for cell proliferation, as shown in Figure 2b . Nevertheless, the percent inhibition of cell proliferation obtained with aODN treatment resulted independent of the adhesion substrate. Taken together, these results indicate that the effects obtained with aODN treatment cannot be ascribed to alterations in cell/ECM interactions.
Inhibition of cyclins expression by uPAR antisense
The study of the PC3 cell cycle revealed that, starting from the second aODN administration (48 h after plating), about 30% of PC3 cells were prevented from entering the S phase. Such a percentage resulted unmodified over the 4 days treatment (Figure 3 ). The absence of pre-G1 accumulation indicated that apoptosis was not involved. Figure 4 shows the FACS analysis evaluation of cyclins' expression after 4 days of ODNs treatment. As shown, aODN treatment resulted in a strong inhibition of cyclin A, B and D expression. A decrease of cyclins' expression was also observed after 48 and 72 h of treatment (not shown).
Similar results were obtained by Western blotting of cyclins, as shown in Figure 5 , which kinetically relates 
Transduction pathways constitutively activated in PC3 cells
Previous data obtained in other malignant cell lines indicated a critical role of uPAR in the regulation of ERK1/2, whose persistent activation (phospho-ERK1/2, pERK1/2) has been shown to constitutively depend on uPAR per se, as a critical component of the cell membrane-associated ERK-activating complex. [5] [6] [7] Therefore, we have studied the transduction pathways involved in sustaining spontaneous growth of PC3 cells. injection, revealed the presence of osteolytic metastasis in the epiphyses of posterior limbs as the most prevalent sites of tumor growth. Previous experiments demonstrated that in our system 4 weeks represented a suitable end point, because we did not observe the formation of further metastases if we waited longer. For these reasons, in order to evaluate the reduction in bone metastasis development, we obtained total body radiography of all mice at the end point and then analyzed the radiographic films by digital scan, considering positive mice with the presence of at least one osteolytic zone (Figure 7a ). Although we divided randomly the animals in three groups, mice number among different groups resulted not homogeneous because of a variable mortality due to the injection practice ( Figure 7b ). All groups received PC3 cells, but aODN and dODN groups were inoculated with PC3 cells that had been treated in vitro with the respective oligonucleotide for 4 days. After the injection of PC3 cells, mice received intraperitoneally once daily 100 ml of saline solution (control group), or 0.5 mg of antisense oligonucleotide (aODN group), or 0.5 mg of degenerated oligonucleotide (dODN group). The experiment was repeated twice according to the same protocol. Mice treated with aODN did not show any significant loss of weight with respect to the mice of the other groups or any signs of distress. Control and dODN groups showed, 28 days after heart injection, a percentage of bone metastases variable from 50 to 80% of the mice (Figure 7c ). Although mice treated with degenerated oligonucleotide showed in all experiments a higher percentage of bone metastases with respect to the control group, the statistical analysis revealed that the differences were not significant. As shown in Figure 6d , the treatment with aODN induced a drastic reduction in the number of metastases with only two cases of bone lesions in 15 mice, and with a reduction of more than 80% in the number of metastases with respect to the control group. When considering also other sites of metastasis (Table 1) , the antimetastatic activity of uPAR aODN resulted even more evident. Mice treated with aODN neither showed any significant loss of body weight nor any signs of distress with respect to mice of the other groups.
Discussion
We examined whether administration of uPAR aODN could inhibit invasion and growth of human prostate cancer PC3 cells in vitro and the development of bone metastases upon intraventricular injection of cells in nude mice. Our data show that PC3 cells express high levels of uPAR, which delivers signals through the FAK/ JNK/Jun pathway. uPAR expression downregulation by aODN determines inhibition of such a transduction pathway, with a parallel impairment of cyclin D1, D3, B and A expression, which results in impairment of PC3 cells' growth. At the same time, uPAR aODN treatment also reduced Matrigel invasion of PC3 cells without significantly affecting their adhesive properties. Intraperitoneal administration of uPAR aODN in nude mice subjected to intraventricular injection of PC3 cells was followed by a complete inhibition of bone metastases development in 80% of treated mice.
Effects of blocking urokinase receptor signaling by aODNs F Margheri et al
The progressive growth of many human carcinomas, including those of the prostate, [10] [11] [12] [13] [14] [15] is associated with overexpression of the uPA/uPAR system. Our results closely agree with those reported in previous studies indicating that inhibition of tumor cell-associated uPAR reduces tumor burden and metastatic spreading of human tumor cells xenografted in nude mice. [16] [17] [18] In PC3 cells, we have observed that uPAR per se, besides its involvement in cell invasion, delivers mitogenic signals independently of its stimulation with uPA, as previously observed for other malignant cells. [5] [6] [7] Although these data do not exclude the possibility of a mitogenic activity of uPA, dependent on its interaction with uPAR, they suggest that impairment of uPAR expression has the chance to control not only invasion but also proliferation of human prostate carcinoma cells. Recently, it has been shown that a balance that favors the uPAR-dependent p38 activation over ERK can induce a persistent growth suppression in highly malignant human carcinoma cells in vivo. 7 Following uPAR downregulation, ERK activity is lost, p38 becomes activated and the balance is shifted in favor of p38. 7 Here we have shown that in PC3 cells, such uPA-independent uPAR activity is mediated by the constitutive FAK/JNK/Jun pathway activation generated by uPAR, and is blocked by uPAR downregulation with aODN, which is paralleled by inhibition of FAK/ JNK/Jun phosphorylation. These data are in agreement with previous observations indicating that the c-Jun NH2-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. 19 Jun belongs to a subgroup of transcription factors (together with Fos and ATF) that form AP-1 dimers. 20 There is evidence that For the RT reaction, 1 mg of total RNA was isolated from control, aODN-treated and dODN-treated PC3 cells. Aliquots of total cDNA were used to amplify uPAR and GAPDH with primers. After 25 cycles of PCR amplification, 10 ml aliquots were taken and separated on a 1% (w/v) agarose gel containing ethidium bromide (1 mg/ml). The PCR products were quantified densitometrically by a laser scanner. Inserts correspond to the ethidium bromide staining of the PCR products, which are numbered according to the ml of amplified cDNA. -'-, control; -K-, aODN; -m-, dODN. Histograms on the right represent the levels of uPAR mRNA in PC3 cells. Three values of uPAR and GAPDH amplificates, falling within the range of linearity, were normalized to the total starting retrotranscripts volumes. Data are expressed as the ratio of uPAR mRNA/GAPDH mRNA. Data reported represent the mean7s.d. of three determinations for each point. *At the 0.05 level of Student's t-test, the two means are significantly different.
Effects of blocking urokinase receptor signaling by aODNs F Margheri et al AP-1 proteins, mostly those that belong to the Jun group, control cell life and death through their ability to regulate the expression and function of cell cycle regulators. 20 Among the Jun proteins, c-Jun positively regulates cell proliferation through the repression of tumor suppressor gene expression and function, and induction of cyclin D1 transcription. 21 These actions are antagonized by JunB, which upregulates tumor suppressor genes and represses cyclin D1. 22 Other evidences indicate that Jun NH2-terminal kinase is required for progression of cells through the G1 phase of the cell cycle. 23 In PC3 cells, we have shown that uPAR signaling through the FAK/JNK/ Jun pathway regulates cyclin D1, D3, B and A expression and cell progression through the cell cycle. uPAR aODN exerts its growth inhibitory effects by downregulation of cyclins that allow the cells to overcome the S phase of the cell cycle. uPAR is part of a large receptor complex including protein kinases and integrins of the beta1, beta2 and beta3 family, [24] [25] [26] its binding to integrins leading to important functional consequences on integrin activity that vary depending on the cell type, such as decrease/increase of integrin-mediated cell adhesion and activation of integrin-dependent signaling.
5,26 uPAR functionally interacts also with G-protein-coupled receptor involved in chemotaxis, the receptor for fMet-LeuPhe peptide (fMPL), 27 the Gp130 transmembrane adapter, 28 the uPAR-associated protein (uPARAP). 29 The glycosyl-phosphatidyl-inositol-(GPI)-tail of uPAR is unable to deliver signals into the cell, and uPAR interaction with cell surface molecules is a crucial point because GPI-uPAR could activate cell signaling pathways by interacting with extracellular domains of transmembrane proteins. 30, 31 Therefore, it is likely that uPAR downregulation achieved with aODN may lead to decrease of signaling by loss of stimulation of uPAR-associated molecules. At the same time, the maintenance of adhesive properties upon treatment indicates that in PC3 cells the cell-ECM interaction mediated by uPARassociated and non-uPAR-associated molecules is not affected by uPAR antisense downregulation.
To study the uPAR aODN control of bone metastases of human PC3 cells in nude mice, we have chosen the model of intracardiac injection of human malignant cells. Animal models that recapitulate the natural progression of human PCa are limited. In particular, several models have been developed in rodents by inducing or implanting tumors in them, but in all cases, the percentage of bone metastases were null or scarce. 32 Bone lesions in PCa models have been generated in animals, either by direct injection into bone marrow 33 or by intravenous injection in the tail vein with vena cava occlusion, 34 or by inoculation into the left ventricle. 35 The use of intracardiac injection of human tumor cells in nude mice represents the closest model to the state of spontaneous metastatic tumor cell spreading through the arterial circulation and has been demonstrated to produce bone lesions in the spine, mandible, ribs and limbs. 36, 37 The PC3 cell line, originally derived from a human bone metastasis of PCa, is able, when injected directly into bone marrow of immunodeficient mice, to generate with high efficiency osteolytic lesions 38 whose appearance may be easily monitored by radiography, In vivo, the methods based on inhibition of uPAR by antibodies and antagonists of uPAR interactions may suffer from some drawbacks, as recently discussed. 18 The relatively low amount of antibody that actually arrives to the tumor, antibody scavenging by tumor-derived soluble antigens (uPAR is one of them), and the possibility that small antagonists of uPAR interactions may stimulate uPAR transductions are only a few examples.
The aODN approach allows one to by-pass such complications and has been successfully applied to inhibit uPAR expression in vitro and in vivo, using either the classic aODN technology, which consists of the injection of antisense DNA strands complementary to uPAR mRNA, 8, 18, 39 or the antisense RNA technology, based on cell transfection with a vector capable of expressing the antisense transcript complementary to uPAR mRNA. 40, 41 It is likely that the efficacy of uPAR aODN in the control of bone metastasis by prostate carcinoma cells in vivo results from the cumulative activity on uPAR-dependent invasion and growth. Our data are not exhaustive only for prostate carcinoma cells, since we have recently shown that uPAR aODNs are able to control the growth and metastatic spreading of human melanoma cells transplanted in nude mice, through a downregulation of uPAR-dependent ERK1/2 phosphorylation. 18 Different transduction pathways are coupled with the uPAR transductosome, depending on the cell line under study. Therefore, one can predict that uPAR aODN downregulation may lead to silencing of each uPAR-associated pathway and that other human tumors, which rely on the uPAR system for their constitutive growth and invasion, could respond to uPAR aODN treatment in vivo. Effects of blocking urokinase receptor signaling by aODNs F Margheri et al were grown as monolayer cultures in DMEM-10% FCS. The culture medium was supplemented with antibiotics and L-glutamine (2 mM) and cells were incubated at 371C in a 5% CO 2 -95% air atmosphere in a humidified incubator. Male CD1 s nude mice (nu/nu mice), 4 weeks old and weighing 14-16 g, used for in vivo bone metastasis experiments, were purchased from Charles River Laboratories (Calco, Italy).
Materials and methods
Cells and animals
Invasion assays
The Boyden chamber was used to evaluate spontaneous invasion of untreated cells (control) and of cells treated with ODNs, as described. 8, 42 The filter separating upper and lower wells was coated with the reconstituted basement membrane Matrigel (50 mg/filter) (a kind gift of Dr Adriana Albini, Genova, Italy). Control untreated cells and cells pretreated for 96 h with ODNs as detailed below, were placed in the upper compartment of the chamber (25 Â 10 3 cells/well) and migration was allowed to occur at 371C for 6 h in the absence (control condition) or in the presence of ODNs in the medium of the upper and the lower compartment of the migration chamber. 
Proliferation studies
Proliferation was evaluated by cell counting. Cells were seeded onto six multiwell plates (Sarstedt, Verona, Italy) in medium supplemented with 10% FCS and were left to adhere overnight. Cells were then extensively washed in phosphate-buffered saline (PBS) and maintained for 24 h in serum-free DMEM. Medium was removed and cells were incubated with 10% FCS in DMEM, in the absence or in the presence of ODNs, as detailed below. Each Values were expressed as the absolute number of cells or as percent variation with respect to basal number, 7s.d.
Studies of adhesion/spreading and proliferation on different substrates
To study adhesion, wells in 24-well plates were coated with 200 ml of PBS (Dulbecco's PBS 10 mM without Ca and Mg) containing various substrates at a concentration of 100 mg/ml (matrigel) or 10 mg/ml (vitronectin, InvitrogenGmbH, San Giuliano Milanese, Italy; fibronectin, Sigma-Aldrich S.r.l., Milano, Italy; lamininin-5, Calbiochem, vWR International S.r.l., Milano, Italy) and were incubated 1 h at 371C. Remaining protein-binding sites were blocked by incubating with DMEM containing 250 mg/ml BSA for 30 min at 371C. After this incubation, wells were washed once with prewarmed serum-free DMEM. PC3 cells ( For proliferation studies on specific substrates, wells of six multiwell plates were coated with 1 ml of substrate-containing solution and further processed as described above. PC3 cells were then plated at the same density described under 'Proliferation studies' and incubated in the presence or in the absence of ODNs as detailed below. After 72 h, cells were detached with EDTA and counted with a cell counter. Values are expressed as mean percent variation7s.d. with respect to basal number at the beginning of ODNs treatment and are representative of three independent experiments performed in triplicate.
uPAR determination by ELISA assay, detection of uPAR and cyclins' transcripts by semiquantitative RT-PCR A monoclonal-antibody-based anti-uPAR assay (American Diagnostica, Greenwich, CT, USA) was used to measure uPAR number. Monolayers of control untreated cells and of cells treated with ODNs for 4 days were lysed with lysis buffer, as suggested by the manufacturer, and an aliquot of the cell lysate was used for uPAR determination. mRNA levels of uPAR gene were determined by an internal-based semiquantitative reverse transcriptase-polymerase chain reaction assay (RT-PCR), as previously described. 8 The primers for cyclins were: cyclin A, sense 5 0 GAG CTA TCC TCG TGG ACT  GG Effects of blocking urokinase receptor signaling by aODNs F Margheri et al cyclin A; 250 bp for cyclin B1; 200 bp for cyclin D1; 210 bp for cyclin D3. The ethidium bromide-stained cDNAs were photographed under a UV transilluminator by using Polaroid positive/negative instant films and quantified as reported elsewhere. 8, 42 Treatment with uPAR aODN in vitro uPAR gene expression was inhibited with an 18-mer phosphorothioate aODN 42 (ISIS Pharmaceuticals, Carlsbad Research Center, CA, USA, product designation: ISIS 17916). The sequence of ISIS 17916 is 5 0 -CGG CGG GTG ACC CAT GTC-3 0 . As negative control, we used a completely degenerated 18-mer ODN (dODN): such ODN is a mixture of all the possible combinations of the bases, which compose the aODN. ODN uptake and stability were enhanced by combining ODNs (10 mmol/l) with a cationic liposome (13 mmol/l), namely DOTAP (Boehringer Mannheim, Mannheim, Germany), following the procedure previously described. 8 Cell cultures were treated daily with ODNs for 4 days, on the basis of preliminary experiments indicating a steady-state reduction of uPAR number and of uPAR mRNA after 3 days of aODN treatment. Since the half-life of cationic lipidcombined ODNs in the culture medium was about 24 h, the initial treatment with 10 mM cationic lipid-combined ODN was followed by a second addition of 5 mM after 24 h in order to restore the initial concentration. 
Western blotting
Control (DOTAP-treated), aODN-and dODN-treated PC3 cells were counted for the indicated times to evaluate the activity of the uPAR aODN on cell proliferation and were lysed in a 10 mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCl, 1% Triton X-100, 15% glycerol, 1 mM sodium orthovanadate, 1 mM NaF, 1 mM Flow cytometry Reagents. Anti-cyclin A rabbit polyclonal antibody was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Fluorescein-conjugate (FITCconjugated) mouse anti-cyclin B1, anti-cyclin D1 and anti-cyclin D3 antibodies reagent sets were purchased from BD PharMingen (San Diego, CA, USA). Mouse IgG2a mAb with irrelevant specificity, used as control, fluorochrome-conjugated anti-IgG2a mAb and FITCconjugated goat anti-rabbit antibody were purchased from Southern Biotechnology Associates (Birmingham, AL, USA). Saponin was purchased from Sigma Chemical Co. (St Louis, MO, USA) and 4 0 ,6-diamidino-2-phenylindole, dihydrochloride (DAPI) from Molecular Probes (Eugene, OR, USA). Anti-human CD87 mouse monoclonal antibody, which identifies total uPAR, was purchased from American Diagnostica (Montrèal, Quebec, Canada).
Surface staining of uPAR. Flow cytometry analysis on PC3 suspensions was performed as described previously. 43, 44 Briefly, 3 Â 10 5 PC3 cells were suspended in PBS containing 0.5% BSA and 0.02% sodium azide and, after saturation of nonspecific binding sites with total rabbit IgG, were incubated for 20 min with anti-CD87 mAb or with an isotype-matched monoclonal antibody (IgG2a). Cells were then washed and incubated with a fluorochrome-conjugated anti-IgG2a mAb for an additional 20 min. Finally, cells were washed and analyzed on a BD-LSR cytofluorimeter (Becton Dickinson).
Cell cycle. PC3 cells were washed once with PBS (pH 7.2), fixed 15 min with formaldehyde (2% in PBS (pH 7.2)); washed once with 0.5% BSA in PBS (pH 7.2), and then incubated for 15 min at room temperature in the dark, with DAPI. Cells were then acquired on a BDLSR cytofluorimeter and analyzed with the Modfit LT software (Verity Software House Inc., Topsham, ME, USA).
Cyclin A, B1 and D1+D3 evaluation. The staining was performed as described elsewhere. 45 Briefly, cells were washed once with PBS (pH 7.2), fixed 15 min with formaldehyde (2% in PBS (pH 7.2)), washed once with 0.5% BSA in PBS (pH 7.2), permeabilized with PBS (pH 7.2) containing 0.5% BSA and 0.5% saponin, and then incubated for 15 min at room temperature with rabbit anti-cyclin A, FITC-conjugated mouse anti-cyclin B1 and FITC-conjugated mouse anti-cyclin D1+anti-cyclin D3, or isotype control antibodies. After incubation, cells were washed twice with PBS (pH 7.2) containing 0.5% BSA and 0.5% saponin; in the indirect staining, this step was followed by a second incubation at room temperature with a FITC-conjugated goat anti-rabbit antibody. Finally, cells were incubated for 15 min, at room temperature in the dark, with DAPI, and were acquired on a BDLSR cytometer by using the CellQuest software. Council, 1996) . Each experimental group included 20 mice. Subconfluent PC3 cells were harvested and washed twice by centrifugation in PBS at room temperature. Immediately prior to injection, cells were resuspended, avoiding cell clusters formation, at a density of 1 Â 10 5 in 0.1 ml of PBS (injected amount). Four weeks old nude mice were anesthetized with a mixture of ketamine/xylazine and were placed in a supine position for heart injection. A 27-gauge needle on a tuberculin syringe containing the cell suspension was inserted in the second left intercostal space 46 and when pulsatile blood appeared in the needle hub, the cell suspension was injected with a continuous and slow movement. Animals were subjected to daily intraperitoneal injection of ODNs. 47 Animals were killed by carbon dioxide inhalation 28 days after heart injections or at first signs of serious distress. The development of metastases in the whole skeletal apparatus was monitored weekly by radiography using a Faxitron cabinet X-ray system (Faxitron X-ray corp., Wheeling, IL, USA). All animals were subjected to necroscopy and portions of various organs were processed for routine histological examination. Radiography-positive bones were subjected to decalcification in 8% nitric acid and analyzed by H&H staining for the presence of tumor cells in bone medulla.
Heart injection of PC3 cells in nude mice
Statistical analysis
Results are expressed as means7s.d. for (n) experiments. Multiple comparisons were performed by the StudentNewman-Keuls test, after demonstration of significant 
